News

The company is showcasing its lasers at the Hawaiian Eye and Retina 2024 meeting, being held January 13-19 at the Grand Wailea Resort in Maui.

Studies aim to develop a clinically useful biomarker of retinal capillary changes to monitor the development of a prevalent form of systemic vascular disease and cerebrovascular disease.

Because acetylcholinesterase inhibitors have anti-inflammatory effects, authors of the study wanted to determine if these drugs reduce the risk of AMD in patients with Alzheimer’s disease.

The GLYCO Phase 2 US clinical trial will evaluate AVD-104 for the management of diabetic macular edema (DME).

The trial will use vision preservation as a primary outcome measure, according to Annexon

eSight, a wearable assistive technology company, produces comprehensive equipment for patients with over 20 ocular disorders

The VISUMAX 800 is the latest generation of Zeiss femtosecond lasers, and offers a reduced laser time when compared to its predecessors.

This trial is a multi-center, open-label safety and tolerability study enrolling 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up.

AR-15512, a topical transient receptor potential melastatin 8 agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. Alcon plans to file a New Drug Application for AR-15512 with the FDA in mid-2024.

Researchers at Indiana University School of Medicine will focus on providing a foundation for developing a new glaucoma therapeutic by testing human neurons and a regenerative therapy to rescue visual neurons from dying preclinically in human eyes under glaucoma conditions.

According to the company, all three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.

According to the company, EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.

Student confidence in dealing with ophthalmic conditions is down, deterring them from considering ophthalmology as a career.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

Sharing, learning, networking, collaborating

A reduction in clinical exposure has harmed student confidence, according to a questionnaire administered in the United Kingdom

eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

Updates include expected timelines for trials for the treatment of wet AMD, DME, GA, and inherited retinal diseases.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

The device is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.

Researchers found the administration of the neuropeptide α–melanocyte–stimulating hormone promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19